Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Suspended 1Recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Neoplasm, Residual 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 78Cyclophosphamide 55Specimen Handling 53Carboplatin 49fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Gemcitabine 37Biopsy 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Cisplatin 24Pemetrexed 23Ipilimumab 22Capecitabine 21Temozolomide 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Fulvestrant 18Cetuximab 18Azacitidine 17Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Biological Assay × 90 days × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT06253494 2026-04-09

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡